GBS Inc. Reports First Quarter 2021 Financial Results and Recent Business Highlights
Anticipate Emergency Use Submission for SARS-CoV-2 Antibody Biosensor Test in the Second Half of 2021. $14 Million in Cash, Cash
Anticipate Emergency Use Submission for SARS-CoV-2 Antibody Biosensor Test in the Second Half of 2021. $14 Million in Cash, Cash
NEW YORK APRIL 15, 2021 – GBS, Inc. (GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests,
New York, NY, February 18, 2021 – GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point
Combination of the Wyss’ electrochemical sensing technology with GBS’s transistor technology could enable fast, multiplexed, low-cost COVID-19 biomarker analysis in
SYDNEY – May 6, 2020 The iQ Group Global is pleased to announce that Life Science Biosensor Diagnostics Pty Ltd
SYDNEY – May 29, 2020 Life Science Biosensor Diagnostics Pty Ltd (LSBD), a development company of The iQ Group Global,
The world’s first non-invasive, saliva-based glucose test for diabetes management SYDNEY – February , 2019 – The iQ Group